05 April 2023, Bangalore: IOL Chemicals and Pharmaceuticals Limited (IOL), a leading manufacturer of pharmaceutical (APIs) and specialty chemicals, has appointed Mr Vikas Vij as the new Chief Executive Officer, with effect from 3rd April 2023. Mr Vij’s role is expected to aid the company to bolster growth across domestic and international markets by leading IOL’s portfolio enhancement and efficiencies.
Mr Vikas Vij has a techno-commercial background with a nuanced understanding of Active Pharmaceutical Ingredients (API), Finished Dosage Forms (FDF), Custom Pharmaceutical Services (CRAMS), specialty chemicals, and operations from his previous leadership roles across the pharma value chain. He was previously associated with Cipla as the Senior Vice President of API and Access Business Units. In his career spanning over 30 years, he has donned various roles in Ranbaxy, GVK Biosciences, Alembic Pharmaceuticals, Sun Pharma, and Apollo Hospitals.
Mr Vikas Gupta – Joint Managing Director of IOL Chemicals and Pharmaceuticals said, “I am delighted to welcome Mr Vikas Vij as CEO of IOL Chemicals and Pharmaceuticals. He is a demonstrated leader who brings in tremendous capabilities of driving sales and scaling businesses in the pharmaceutical and specialty chemicals domains. We are confident that his experience across the board will empower us to drive transformational growth for IOL nationally as well as in advanced and emerging markets.”
On his appointment, Mr Vikas Vij – Chief Executive Officer of IOL Chemicals and Pharmaceuticals said, “I am excited to work with the dynamic workforce at IOL to drive its next phase of growth. It is a great privilege to lead a company that is making a significant impact on people’s lives and to the growth of the Indian Pharmaceutical Industry.”
Mr Vikas Vij takes over from Dr Sanjay Chaturvedi.
About IOL Chemicals and Pharmaceuticals Limited (IOLCP)
Company was established in 1986, listed on National Stock Exchange of India Ltd (Code: IOLCP) and BSE Ltd (Code: 524164) is one of the leading pharmaceutical (APIs) Company and is significant player in the specialty chemicals space with world class facilities. IOLCP has wide presence across major therapeutic categories like, Pain Management, anti-convulsants, anti-diabetes, anti-cholesterol and anti-platelets.
The Company’s product portfolio includes APIs; Ibuprofen, Metformin, Fenofibrate, Clopidogrel, Lamotrigine, Pantoprazole, Paracetamol and specialty chemicals such as Ethyl Acetate, Iso Butyl Benzene, Mono Chloro Acetic Acid and Acetyl Chloride.
Company is World’s largest producer of the Ibuprofen with an installed capacity of 12,000 TPA and having backward integrated manufacturing facility. The Company has DSIR approved R&D which is fully equipped to validate existing processes.
The Central and State Government approved Effluent Treatment Plant (ETP) had been set up with Zero Liquid Discharge (ZLD) system along with 17 MW captive Co-Generation plant for self -reliance. The Company is ISO 9001:2015, 14001:2015 and BS OHSAS 18001:2007 certified.
IOLCP's overseas customers are spread out across several countries including UK, Belgium, Hungry, Spain, Germany, Italy, Netherlands, Switzerland, Poland, Ireland, USA, Peru, Brazil, Argentina, Colombia, Indonesia, South Korea, Thailand, Bangladesh, Turkey, U.A.E., China, Hong Kong, Egypt etc. Products are sold primarily to Branded Generic formulators both in India & Overseas.
*Disclamier: "The pages slugged ‘Press Release’ are equivalent to advertisements and are not written and produced by Success Insights India Media journalists/Editorial." We do not hold any copyrights towards the content or image. Image source: Newswire